{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:02:43Z","timestamp":1790085763649,"version":"4.0.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Poorly differentiated gastric adenocarcinoma with squamous differentiation is a rare and aggressive malignancy, with limited representation in the literature. Its biological behaviour remains poorly characterized, and prognosis is generally poor. Here, we present a case that highlights the role of biomarker-driven, non-surgical management in advanced gastric malignancy, particularly in the context of high PD-L1 expression in an elderly patient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 75-year-old Syrian Arab male presented with anaemia, weight loss and anorexia. Imaging revealed a large ulcerated gastric mass measuring 9\u2009\u00d7\u200911 cm with perigastric lymphadenopathy and local invasion, but no evidence of distant metastasis. Histopathological examination confirmed poorly differentiated adenocarcinoma with squamous differentiation. Immunohistochemistry demonstrated diffuse p40 positivity and focal cytokeratin 7 (CK7) positivity. Notably, programmed death-ligand 1 (PD-L1) expression was strongly positive, with a combined positive score (CPS) of 75. The patient was started on combined chemotherapy (oxaliplatin and 5-fluorouracil) and immunotherapy (nivolumab). Remarkably, follow-up positron emission tomography\u2013computed tomography (PET-CT) at 3 months showed a reduction in tumour size and metabolic activity, with near complete radiological remission by 6 months. At 1-year follow-up, the patient remains clinically well and disease-free without surgical intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case illustrates how high PD-L1 expression may substantially alter the expected clinical course of gastric cancer, even in rare and poorly differentiated subtypes typically associated with poor outcomes. The observed durable clinical complete response underscores the potential of biomarker-guided chemo-immunotherapy and supports consideration of non-surgical approaches in selected patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13256-026-06440-x","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:44:43Z","timestamp":1785512683000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Successful non-surgical management of locally advanced gastric adenocarcinoma with squamous differentiation and programmed death-ligand 1 combined positive score 75: a case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Sandy","family":"Ghadeer Jalloul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joudi","family":"Ghadeer Jalloul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ghadeer Jalloul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"issue":"4","key":"6440_CR1","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2023.2677","volume":"19","author":"G De Lange","year":"2023","unstructured":"De Lange G, Bouroumeau A, Coron E, Koessler T. Gastric squamous cell carcinoma: a rare malignancy, literature review and management recommendations (review). Mol Clin Oncol. 2023;19(4): 81. https:\/\/doi.org\/10.3892\/mco.2023.2677.","journal-title":"Mol Clin Oncol"},{"issue":"7","key":"6440_CR2","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1002\/1097-0142(20001001)89:7<1418::AID-CNCR2>3.0.CO;2-A","volume":"89","author":"Y Adachi","year":"2000","unstructured":"Adachi Y, Yasuda K, Inomata M, Sato K, Shiraishi N, Kitano S. Pathology and prognosis of gastric carcinoma: well versus poorly differentiated type. Cancer. 2000;89(7):1418\u201324.","journal-title":"Cancer"},{"issue":"1","key":"6440_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.21037\/jgo.2018.10.06","volume":"10","author":"M Akce","year":"2019","unstructured":"Akce M, Jiang R, Alese OB, Shaib WL, Wu C, Behera M, El-Rayes BF. Gastric squamous cell carcinoma and gastric adenosquamous carcinoma, clinical features and outcomes of rare clinical entities: a National Cancer Database (NCDB) analysis. J Gastrointest Oncol. 2019;10(1):85\u201394. https:\/\/doi.org\/10.21037\/jgo.2018.10.06.","journal-title":"J Gastrointest Oncol"},{"key":"6440_CR4","unstructured":"Weisenberg E. Gastric adenosquamous carcinoma. PathologyOutlines.com website. https:\/\/www.pathologyoutlines.com\/topic\/stomachadenosquamouscarc.html. Accessed 14 Mar 2026."},{"issue":"3","key":"6440_CR5","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.21037\/jgo-22-1133","volume":"14","author":"RD Peixoto","year":"2023","unstructured":"Peixoto RD, Mathias-Machado MC, J\u00e1come A, et al. PD-L1 testing in advanced gastric cancer-what physicians who treat this disease must know-a literature review. J Gastrointest Oncol. 2023;14(3):1560\u201375. https:\/\/doi.org\/10.21037\/jgo-22-1133.","journal-title":"J Gastrointest Oncol"},{"key":"6440_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2026.02.003","author":"YY Janjigian","year":"2026","unstructured":"Janjigian YY, Shitara K, Ajani JA, et al. Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649. Ann Oncol. 2026. https:\/\/doi.org\/10.1016\/j.annonc.2026.02.003.","journal-title":"Ann Oncol"},{"key":"6440_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-66701-x","volume":"14","author":"Y Du","year":"2024","unstructured":"Du Y, Tian H, Chen Z, et al. Analysis of clinicopathological characteristics and prognosis on primary gastric adenosquamous carcinoma. Sci Rep. 2024;14: 16198. https:\/\/doi.org\/10.1038\/s41598-024-66701-x.","journal-title":"Sci Rep"},{"issue":"3","key":"6440_CR8","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/modpathol.2011.173","volume":"25","author":"JA Bishop","year":"2012","unstructured":"Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N. P40 (\u0394Np63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Modern Pathol. 2012;25(3):405\u201315. https:\/\/doi.org\/10.1038\/modpathol.2011.173.","journal-title":"Modern Pathol"},{"issue":"6","key":"6440_CR9","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1097\/JCMA.0000000000000922","volume":"86","author":"CH Wu","year":"2023","unstructured":"Wu CH, Lai CL, Teng CJ, Fang WL, Huang KH, Fen-Yau Li A, Yu HY, Chiang NJ, Chao Y, Hung YP, Chen MH. Immunoprofile of adenosquamous carcinoma in gastric cancer. J Chin Med Assoc JCMA. 2023;86(6):542\u20138. https:\/\/doi.org\/10.1097\/JCMA.0000000000000922.","journal-title":"J Chin Med Assoc JCMA"},{"issue":"14","key":"6440_CR10","doi-asserted-by":"publisher","first-page":"4385","DOI":"10.3748\/wjg.v21.i14.4385","volume":"21","author":"A Shirahige","year":"2015","unstructured":"Shirahige A, Suzuki H, Oda I, Sekiguchi M, Mori G, Abe S, Nonaka S, Yoshinaga S, Sekine S, Kushima R, Saito Y, Fukagawa T, Katai H. Fatal submucosal invasive gastric adenosquamous carcinoma detected at surveillance after gastric endoscopic submucosal dissection. World J Gastroenterol. 2015;21(14):4385\u201390. https:\/\/doi.org\/10.3748\/wjg.v21.i14.4385.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"6440_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10030543","volume":"10","author":"S Choi","year":"2022","unstructured":"Choi S, Park S, Kim H, Kang SY, Ahn S, Kim K-M. Gastric cancer: mechanisms, biomarkers, and therapeutic approaches. Biomedicines. 2022;10(3): 543. https:\/\/doi.org\/10.3390\/biomedicines10030543.","journal-title":"Biomedicines"},{"key":"6440_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","volume":"17","author":"L Galluzzi","year":"2017","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O, et al. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol. 2017;17:97\u2013111. https:\/\/doi.org\/10.1038\/nri.2016.107.","journal-title":"Nat Rev Immunol"},{"key":"6440_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1552052","volume":"16","author":"YY Lei","year":"2025","unstructured":"Lei YY, Li L, Shi YB, Han XH, Li YT, Ren WJ, Sui AX. Case report: long-term response control in a patient with metastatic gastric squamous cell carcinoma treated with nivolumab and chemoradiotherapy. Front Immunol. 2025;16: 1552052. https:\/\/doi.org\/10.3389\/fimmu.2025.1552052.","journal-title":"Front Immunol"},{"issue":"24","key":"6440_CR14","doi-asserted-by":"publisher","first-page":"12270","DOI":"10.18632\/aging.102567","volume":"11","author":"R Chen","year":"2019","unstructured":"Chen R, Chen Y, Huang G, Liu J. Relationship between PD-L1 expression and 18F-FDG uptake in gastric cancer. Aging (Albany NY). 2019;11(24):12270\u20137. https:\/\/doi.org\/10.18632\/aging.102567.","journal-title":"Aging (Albany NY)"},{"issue":"4","key":"6440_CR15","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clinical Practice, 2012;120(4):c179\u2013c184. https:\/\/doi.org\/10.1159\/000339789","journal-title":"Nephron Clinical Practice"},{"issue":"10","key":"6440_CR16","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.2215\/CJN.02780312","volume":"7","author":"MA Perazella","year":"2012","unstructured":"Perazella MA. Onco-nephrology: renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol. 2012;7(10):1713\u201321. https:\/\/doi.org\/10.2215\/CJN.02780312.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"6440_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000091","volume":"1","author":"V Launay-Vacher","year":"2016","unstructured":"Launay-Vacher V, Janus N, Deray G. Renal insufficiency and cancer treatments. ESMO Open. 2016;1(4): e000091. https:\/\/doi.org\/10.1136\/esmoopen-2016-000091.","journal-title":"ESMO Open"},{"key":"6440_CR18","doi-asserted-by":"publisher","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino, JM, Chau I, Ernstoff, MS, Gardner, JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, National Comprehensive Cancer Network, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385.","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"6440_CR19","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/549843","volume":"2015","author":"YX Song","year":"2015","unstructured":"Song YX, Huang XZ, Gao P, Sun JX, Chen XW, Yang YC, Zhang C, Liu HP, Wang HC, Wang ZN. Clinicopathologic and prognostic value of serum carbohydrate antigen 19\u20139 in gastric cancer: a meta-analysis. Dis Markers. 2015;2015: 549843. https:\/\/doi.org\/10.1155\/2015\/549843.","journal-title":"Dis Markers"},{"key":"6440_CR20","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/sj.bjc.6601263","volume":"89","author":"C Ziske","year":"2003","unstructured":"Ziske C, Schlie C, Gorschl\u00fcter M, et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer. 2003;89:1413\u20137. https:\/\/doi.org\/10.1038\/sj.bjc.6601263.","journal-title":"Br J Cancer"},{"issue":"2","key":"6440_CR21","doi-asserted-by":"publisher","DOI":"10.5812\/jjcmb.114298","volume":"12","author":"R Salimi","year":"2021","unstructured":"Salimi R, Bagheri S, Kheradmand P, Mansouri E, Seyedtabib M. Evaluation of relationship between cytokeratin 7 expression with some prognostic factors in gastric and colorectal adenocarcinomas. Jentashapir J Cell Mol Biol. 2021;12(2): e114298. https:\/\/doi.org\/10.5812\/jjcmb.114298.","journal-title":"Jentashapir J Cell Mol Biol"},{"issue":"4","key":"6440_CR22","first-page":"229","volume":"6","author":"M Jalali-Nadooshan","year":"2015","unstructured":"Jalali-Nadooshan M, Siadati S, Davati A, Torabi Parizi G, Ghasemi S. Cytokeratin7 expression in gastric and colorectal adenocarcinoma: correlation with prognostic factors. Caspian J Intern Med. 2015;6(4):229\u201332.","journal-title":"Caspian J Intern Med"},{"issue":"2","key":"6440_CR23","doi-asserted-by":"publisher","first-page":"743","DOI":"10.21037\/jgo-2024-884","volume":"16","author":"YH Chen","year":"2025","unstructured":"Chen YH, Joung B, Castillo DR, Brar G. Primary gastric squamous cell carcinoma in a young adult with immunotherapy complications: a case report. J Gastrointest Oncol. 2025;16(2):743\u20139. https:\/\/doi.org\/10.21037\/jgo-2024-884.","journal-title":"J Gastrointest Oncol"},{"key":"6440_CR24","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1200\/JCO.2026.44.2_suppl.809","volume":"44","author":"Al-Bitar Ahmad","year":"2026","unstructured":"Ahmad Al-Bitar et al. Assessing barriers to cancer care in a war zone: a study of challenges facing patients withGI cancers in Syria. J Clin Oncol 2026;44:809. https:\/\/doi.org\/10.1200\/JCO.2026.44.2_suppl.809","journal-title":"J Clin Oncol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-026-06440-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06440-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-026-06440-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:22:48Z","timestamp":1790083368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13256-026-06440-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6440"],"URL":"https:\/\/doi.org\/10.1186\/s13256-026-06440-x","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required for this case report as it describes a single patient\u2019s clinical course and contains no identifying information. Institutional Review Board (IRB) is not required at our institution for the publication of a single retrospective case report that does not involve experimental interventions on humans or animals.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written and informed consent was obtained from the patient for publication of this case and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of the journal on request.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interest.","order":3,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"562"}}